NasdaqGS - Nasdaq Real Time Price USD

Contineum Therapeutics, Inc. (CTNM)

3.9400
+0.1000
+(2.60%)
At close: May 15 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
50,000
0
0
Operating Expense
50,894
50,894
33,923
22,720
28,647
Operating Income
-50,894
-50,894
16,077
-22,720
-28,647
Net Non Operating Interest Income Expense
8,905
8,905
4,398
373
-255
Other Income Expense
-269
-269
2,695
-1,906
-99
Pretax Income
-42,258
-42,258
23,170
-24,253
-29,001
Tax Provision
0
0
450
0
--
Net Income Common Stockholders
-42,258
-42,258
22,720
-24,253
-29,001
Diluted NI Available to Com Stockholders
-42,258
-42,258
22,720
-24,253
-29,001
Basic EPS
-0.36
-2.18
0.84
-1.45
-1.74
Diluted EPS
-0.36
-2.18
0.84
-1.45
-1.74
Basic Average Shares
25,736.0760
19,352.8590
27,055.7900
16,674.1480
16,674.1480
Diluted Average Shares
25,736.0760
19,352.8590
27,055.7900
17,760.6900
17,760.6900
Total Operating Income as Reported
50,894
50,894
-16,077
-22,720
-28,647
Total Expenses
50,894
50,894
33,923
22,720
28,647
Net Income from Continuing & Discontinued Operation
-42,258
-42,258
22,720
-24,253
-29,001
Normalized Income
-42,152
-42,152
19,903.7790
-22,439
-28,993
Interest Income
8,905
8,905
4,606
761
77
Interest Expense
0
0
208
388
332
Net Interest Income
8,905
8,905
4,398
373
-255
EBIT
-42,258
-42,258
23,378
-23,865
-28,669
EBITDA
-42,000
-42,000
23,573
-23,536
-28,344
Reconciled Depreciation
258
258
195
329
325
Net Income from Continuing Operation Net Minority Interest
-42,258
-42,258
22,720
-24,253
-29,001
Total Unusual Items Excluding Goodwill
-106
-106
2,872
-1,814
-8
Total Unusual Items
-106
-106
2,872
-1,814
-8
Normalized EBITDA
-41,894
-41,894
20,701
-21,722
-28,336
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
55.7790
0
0
12/31/2021 - 4/5/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MBX MBX Biosciences, Inc.
10.65
+4.72%
 
AVBP ArriVent BioPharma, Inc.
19.24
+2.61%
 
BCAX Bicara Therapeutics Inc.
14.47
+5.62%
 
ARTV Artiva Biotherapeutics, Inc.
2.1300
+17.68%
 
RAPP Rapport Therapeutics, Inc.
9.76
+1.30%
 
EQ Equillium, Inc.
0.3900
+4.47%
 
ZBIO Zenas BioPharma, Inc.
9.74
+12.21%
 
UPB Upstream Bio, Inc.
8.78
+2.57%
 
CGEM Cullinan Therapeutics, Inc.
7.24
+1.54%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.4400
-1.37%